



## **CSAM Health Group AS**

Quarterly Report Q2-23 25 August 2023 Emergency response and healthcare niche software

The leading provider in the Nordics, growing across Europe and beyond


## CSAM's software facilitates life-changing milestones

# Vital solutions for 500 healthcare and emergency response organisations across 27 countries
























### From Nordic to Pan-European - and beyond



Note: YTD 2022/2023 split

## BIB integration project portfolio towards final delivery




## **Q2** performance per Business Area


MEDICATION 4% MANAGEMENT		WOMEN AND 12% CHILDREN'S HEALTH		MEDICA	L IMAGINC <sup>7%</sup>	CONNECTED 13% HEALTHCARE	
Sales	3,6 MNOK	Sales	13,3 MNOK	Sales	7,2 MNOK	Sales	13,3 MNOK
EBITDA	37%	EBITDA	39%	EBITDA	11%	EBITDA	9%
Capex	2%	Capex	<mark>5</mark> %	Capex	24%	Capex	6%
Organic growth	-3%	Organic growth	16%	Organic growth	-4%	Organic growth	14%

	ALTH 6%		PUBLIC 45% SAFETY			LIMS - BLOOD 13% MANAGEMENT		
Sales	5,8 MNOK	Sales	46,4 MN	OK	Sales	13,0 MN	OK	
EBITDA	-6%	EBITDA	1:	5%	EBITDA	-3	2%	
Capex	0%	Capex	1:	3%	Capex	and the second se	3%	
Organic growth	-21%	Organic growth	20	0%	Organic growth	1	0%	

### Main target: A viable 30% reported EBITDA margin




### Q2-23 Main takeaways




# FINANCIALS

### CSAM's recurring software revenues are steadily increasing




Note: Quarterly revenue development recurring revenue LFQ (NOKm)


### Favourable revenue mix




## Cost improvements to continue throughout 2023



### EBITDA margin will gradually move towards 30%



### Net working capital development




### Comments

•CSAM has a communicated NWC target of -10% or better

•When acquiring companies, it takes some time before CSAMs NWC policies are applied in the acquired companies, hence NWC development will vary.

• Dissolving of Triginta accruals and increased sales and deliveries explain the deviation


### CSAM investors per August 2023



# **Concluding remarks**

- 1. Organic growth
- 2. Profitability
- 3. M&A high activity, but will remain disciplined
- 4. Decentralised and empowered organisation
- 5. Gradual improvements next quarters

### Where we came from and where we are heading



### **Our ambitions remain**



Current long term recurring revenues

Focus on specialised software for healthcare

Large underlying market with structural growth

2021

# Subscribe to our newsletter

### Subscribe to our news

#### First Name

#### Last Name


### Email address

### **News Types**

- Financial News
- General News

I have read and agree to the terms & conditions





# Thank you!